Mironid Gets Roche Backing To Tackle Hereditary Kidney Disease

These are interesting times for Mironid, a Glasgow-based biotech developing small molecule therapeutics for the treatment of autosomal dominant polycystic kidney disease, a life-threatening hereditary condition.

Neil Wilkie
Neil Wilkie • Source: Mironid

Scotland's Mironid is moving from discovery into drug development, armed with fresh venture capital from Roche Holding AG and a promising candidate that could shake up the autosomal dominant polycystic kidney disease (ADPKD) space.

Key Takeaways:

  • Mironid has raised £35m in total to advance its preclinical ADPKD candidate 

Mironid, which raised £4.3m in June 2016 in its Series A financing, has announced an extension of that round, bringing...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Genitourinary

More from Therapeutic Category